Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer

Phase 1/2 Unknown 88 enrolled Sun Yat-sen University

Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluates the effectiveness and safety of Surufatinib combined with chemotherapy plus Toripalimab or not for the first-line treatment of SCLC, and maintenance therapy are Surufatinib combined with Toripalimab or not.

Timeline

Start: 2021-11-09
Primary completion: 2023-12-31
Completion: 2024-12-31

Publications

Zhang Y, Huang Y, Yang Y, Zhao Y, Zhou T, Chen G, Zhao S, Zhou H, Ma Y, Hong S, Zhao H, Zhang L, Fang W. Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial. Signal Transduct Target Ther. 2024 Sep 27;9(1):255. doi: 10.1038/s41392-024-01974-2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Surufatinib	Small molecule	200 mg	Oral
Subject	Toripalimab	Monoclonal antibody	240 mg	Intravenous
Background	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Background	Etoposide	Small molecule	100 mg/m2	Intravenous

Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer

Summary

Timeline

Publications

Drugs

Indications